

# **Cleveland Clinic Laboratories**

#### Technical Update • October 2024

Cleveland Clinic Laboratories is dedicated to keeping you updated and informed about recent testing changes. This Technical Update is provided on a monthly basis to notify you of any changes to the tests in our catalog.

Recently changed tests are bolded, and they could include revisions to methodology, reference range, days performed, or CPT code. Deleted tests and new tests are listed separately. For your convenience, tests are listed alphabetically and order codes are provided.

To compare the new information with previous test information, refer to the online Test Directory at clevelandcliniclabs. com. Test information is updated in the online Test Directory on the Effective Date stated in the Technical Update. Please update your database as necessary.

For additional detail, contact Laboratory Customer Service at 216.444.5755 or 800.628.6816, or via email at clientservices@ccf.org.

Acate *	Summary of Changes by Test Name	Nai: Order Code	the change	test Disc Test New Test	Special In-	coecimen Rey	Component	Meur	Day Reference	performed.	AReported	stability	CPT
2	Acylglycines, Quantitative Analysis, Urine												
2	Adiponectin												
2–3	Bile Acids, Total												
8	Brivaracetam												
8	Chitotriosidase Assay												
3	Drug Detection Panel, Meconium, Qualitative												
3	Drug Detection Panel, TOF-MS, Umbilical Cord Tissue												
3	Enterovirus by PCR												
3	Ethosuximide												
4	Gabapentin												
4	Lacosamide												
4	Macroprolactin												
4	Oxalate, Plasma												
8	Perampanel												
5	Phenobarbital, Free												
5	Pregabalin												
5	Prolactin, Dilution Study												
6	Rufinamide												
8	Telomere Biology Disorders Panel												
6	Testosterone, bioavailable and total by immunoassay (adult males, or individuals on testosterone therapy)												

Aste .		Nar. Ordet Code	me Change	Test Disc New Test	special In-	coecimen Reor	component.	Mer. change(s)	Day Referen	NS Performeun	AReported	stability	CRI
6	Testosterone, bioavailable and total by MS (adult females, children, or individuals on testosterone- suppressing therapy)												
6–7	Testosterone, free and total, by equilibrium ultrafiltration mass spectrometry												
7	Testosterone, total by immunoassay (adult males, or individuals on testosterone therapy)												
7	Varicella-Zoster IgG Ab												
7	Vasoactive Intestinal Polypeptide (VIP), Plasma												

#### Test Changes

Acylglycines, Quantitative Analysis, UrineUQACYLSpecial Information: Submit Patient History for specimen. Clinical information is necessary for required information includes age, gender, diet and family history.AdiponectinADIPCPT: 83520Bile Acids, TotalBILETOFor interface clients only-Test build may need Special Information: The reference intervals for obtained using fasting blood specimens. Refer er 20 ware add programmer and program	appropriate interpretation. Additional (e.g., TPN therapy), drug therapy, I to be modified or adults >20 years old were	effective immediately effective immediately 11/21/24
Bile Acids, Total BILETO For interface clients only–Test build may need Special Information: The reference intervals for obtained using fasting blood specimens. Refer	or adults $>$ 20 years old were	immediately
Special Information: The reference intervals for obtained using fasting blood specimens. Refer	or adults $>$ 20 years old were	11/21/24
<ul> <li>&lt; 20 years old and pregnant women were obtispecimens.</li> <li>Clinical Limitation: Total bile acid concentrating hence, samples should be collected under fass to women with intrahepatic cholestasis of pregtesting and samples should be postprandial.</li> <li>This serum bile acid assay should not be used ursodeoxycholic acid, nor should it be used as or diagnosis of genetic disorders of bile acid so r diagnosis of collection and refrigerate. *OR* 1 mL plasma from EDT/ Centrifuge and transfer the plasma to a plastic collection and refrigerate.</li> <li>Stability:</li> <li>Ambient: 48 hours</li> <li>Refrigerated: 30 days</li> <li>Fr</li></ul>	ained using random blood draw on in serum is increased after meals; ting conditions. This does not apply gnancy who will need peak bile acid d for patients receiving s the primary assay for the screening ynthesis. titative determination of total bile um separator (Gold) tube; y at room temperature. Centrifuge DR* 1 mL serum from red plain tube; ely at room temperature. Centrifuge within 2 hours of collection and teparin (Green) tube; Refrigerated; c CCL tube within 2 hours of from lithium heparin plasma entrifuge within 2 hours of collection A (Lavender) tube; Refrigerated;	

Test Name	Order Code	Change	Effective Date
Bile Acids, Total (continued from page 2)	BILETO	Reference Range:         0 Days to 5 Months: None established         6 Months to 23 Months: < 25.8 umol/L	11/21/24
Drug Detection Panel, Meconium, Qualitative	MECDRG	CPT: 80323/G0480; 80325/G0480; 80345/G0480; 80346/G0480; 80348/ G0480; 80353/G0480; 80354/G0480; 80355/G0480; 80356/G0480; 80358/ G0480; 80359/G0480; 80360/G0480; 80361/G0480; 80362/G0480; 80365/ G0480; 80368/G0480; 80372/G0480; 80373/G0480; 83992/G0480	effective immediately
Drug Detection Panel, TOF-MS, Umbilical Cord Tissue	DRGTOF	CPT: 80325/G0480; 80345/G0480; 80346/G0480; 80348/G0480; 80353/G0480; 80354/G0480; 80355/G0480; 80356/G0480; 80358/G0480; 80359/G0480; 80361/G0480; 80363/G0480; 80365/G0480; 80368/G0480; 80372/G0480; 80373/G0480; 83992/G0480	effective immediately
Enterovirus by PCR	ENTNAS	<b>Special Information:</b> Specimen source required. Heparinized specimens will be rejected. For cerebrospinal fluid (CSF) specimens, <b>the Meningitis Encephalitis Panel (MGEBF) is suggested as an alternate.</b> This test is New York DOH approved.	effective immediately
Ethosuximide	ETHO	For interface clients only-Test build may need to be modified	11/19/24
		Special Information: Collect the specimen before the next dose (trough).	
		Unacceptable conditions: Whole blood, gel separator tubes.	
		Clinical Information: Monitoring concentrations in serum or plasma to assess drug therapy and patient compliance.	
		Specimen Requirement: 1 mL serum from no additive (Red) tube; Refrigerated; Timing of specimen collection: Pre-dose (trough). Do not collect in a gel separator tube. Centrifuge and transfer the plasma/serum to a plastic CCL tube within 2 hours of collection and refrigerate. Transport and store at refrigerated temperature. *OR* 1 mL plasma from green lithium heparin no-gel tube; Refrigerated; Timing of specimen collection: Pre-dose (trough). Do not collect in a gel separator tube. Centrifuge and transfer the plasma/serum to a plastic CCL tube within 2 hours of collection and refrigerate. Transport and store at refrigerated temperature.	
		Stability: Ambient: After separation from cells: 24 hours Refrigerated: After separation from cells: 14 days Frozen: After separation from cells: 30 days	
		Methodology: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)	
		Reference Range: 40.0–100.0 ug/mL Urgent: > 150.0 ug/mL	
		Days Performed: Mon-Sat	
		Reported: 1–3 days	

Test Name	Order Code	Change	Effective Date
Gabapentin	GABA	For interface clients only-Test build may need to be modified Special Information: Collect the specimen before the next dose (trough). Unacceptable conditions: Whole blood, gel separator tubes. Clinical Information: Monitoring concentrations in serum or plasma to assess drug therapy and patient compliance. Specimen Requirement: 1 mL serum from no additive (Red) tube; Minimum: 0.5 mL; Refrigerated; Timing of specimen collection: Pre-dose (trough). Do not collect in a gel separator tube. Centrifuge and transfer the plasma/serum to a plastic CCL tube within 2 hours of collection and refrigerate. Transport and store at refrigerated temperature. *OR* 1 mL plasma from green lithium heparin no-gel tube; Minimum: 0.5 mL; Refrigerated; Timing of specimen collection: Pre-dose (trough). Do not collect in a gel separator tube. Centrifuge and transfer the plasma/serum to a plastic CCL tube within 2 hours of collection and refrigerate. Transport and store at refrigerated temperature. *OR* 1 mL plasma from green lithium heparin no-gel tube; Minimum: 0.5 mL; Refrigerated; Timing of specimen collection: Pre-dose (trough). Do not collect in a gel separator tube. Centrifuge and transfer the plasma/serum to a plastic CCL tube within 2 hours of collection and refrigerate. Transport and store at refrigerated temperature. Stability: Ambient: After separation from cells: 24 hours Refrigerated: After separation from cells: 14 days Frozen: After separation from cells: 30 days Reference Range: 2.0–20.0 ug/mL Days Performed: Mon–Sat Reported: 1–3 days	10/22/24
Lacosamide	LACOS	For interface clients only–Test build may need to be modified Includes: Lacosamide Note: Desmethyllacosamide has been removed Clinical Information: Antiepileptic drug. Expected concentration of patients receiving 200-400 mg/day is 2.2-19.8 ug/mL for Lacosamide. Toxic range not established.	11/19/24
Macroprolactin	MACPRO	<ul> <li>Note: Special Information and Clinical Information have been removed</li> <li>Specimen Requirement: 2 mL serum from serum separator (Gold) tube; Minimum 1 mL; Frozen; Patient must be awake for at least two hours before collection. Separate serum from cells ASAP or within 45 minutes of collection and transfer into standard aliquot tube. Separate specimens must be submitted when multiple tests are ordered. *OR* 2 mL serum from no additive (Red) tube; Minimum 1 mL; Frozen; Patient must be awake for at least two hours before collection. Separate serum from cells ASAP or within 45 minutes of collection and transfer into standard aliquot tube. Separate specimens must be submitted when multiple tests are ordered. *OR* 2 mL plasma from sodium or lithium heparin (Green) tube; Minimum 1 mL; Frozen; Patient must be awake for at least two hours before collection. Separate plasma from cells ASAP or within 45 minutes of collection and transfer into standard aliquot tube. Separate specimens must be submitted when multiple tests are ordered.</li> <li>Stability:</li> <li>Ambient: After separation from cells: 14 days</li> <li>Frozen: After separation from cells: 6 months</li> <li>Methodology: Electro Chemiluminescence Immunoassay (ECLIA)</li> <li>Reference Range:</li> <li>Prolactin: Refer to report</li> <li>Monomeric Prolactin: Refer to report</li> <li>Monomeric Prolactin: Refer to report</li> <li>Monomeric Prolactin Percent: Refer to report</li> <li>Days Performed: Varies</li> <li>Reported: 6–11 days</li> </ul>	11/21/24
Oxalate, Plasma	OXLATE	Specimen Requirement: 3 mL plasma from lithium heparin (green) no-gel tube; Minimum: 2 mL; Place specimen on ice after draw. Critical frozen; Patient should avoid ingestion of vitamin C for 24 hours prior to sample collection. Fasting for 8 hours is recommended, but not required. Separate plasma from cells ASAP or within 1 hour of collection, transfer to standard aliquot tube, and freeze immediately.	11/19/24

Test Name	Order Code	Change	Effective Date
Phenobarbital, Free	PHENFR	Special Information: Gel barrier tubes are not recommended.	11/21/24
		Clinical Information: This test is useful for therapeutic drug management. Trough levels are most reproducible.	
		Specimen Requirement: 3 mL plasma from sodium or lithium heparin (Green) tube; Minimum: 1.2 mL; Refrigerated; Gel-barrier tubes are not recommended. Separate plasma from cells within 2 hours of collection and transfer to standard aliquot tube. *OR* 3 mL serum from no additive (Red); Minimum: 1.2 mL; Gel- barrier tubes are not recommended. Separate serum from cells within 2 hours of collection and transfer to standard aliquot tube. Stability: Ambient: After separation from cells: 72 hours	
		Refrigerated: After separation from cells: Acceptable Frozen: After separation from cells: Acceptable	
		Methodology: Immunoassay (IA) Ultrafiltration (ULT)	
		Reported: 4–8 days	
Pregabalin	PBALIN	For interface clients only-Test build may need to be modified	11/19/24
		Special Information: Collect the specimen before the next dose (trough).	
		Unacceptable conditions: Whole blood, gel separator tubes.	
		Clinical Information: Monitoring concentrations in serum or plasma to assess drug therapy and patient compliance.	
		Specimen Requirement: 1 mL serum from no additive (Red) tube; Minimum 0.5 mL; Refrigerated; Timing of specimen collection: Pre-dose (trough). Do not collect in a gel separator tube. Centrifuge and transfer the plasma/serum to a plastic CCL tube within 2 hours of collection and refrigerate. Transport and store at refrigerated temperature. *OR* 1 mL plasma from green lithium heparin no-gel tube; Minimum: 0.5 mL; Refrigerated; Timing of specimen collection: Pre-dose (trough). Do not collect in a gel separator tube. Centrifuge and transfer the plasma/serum to a plastic CCL tube within 2 hours of collection and refrigerate. Transport and store at refrigerated temperature. *OR* 1 mL plasma from green lithium heparin no-gel tube; Minimum: 0.5 mL; Refrigerated; Timing of specimen collection: Pre-dose (trough). Do not collect in a gel separator tube. Centrifuge and transfer the plasma/serum to a plastic CCL tube within 2 hours of collection and refrigerate. Transport and store at refrigerated temperature.	
		Stability: Ambient: After separation from cells: 24 hours Refrigerated: After separation from cells: 14 days Frozen: After separation from cells: 30 days	
		Methodology: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)	
		Reference Range: 2.0–8.0 ug/mL	
		Days Performed: Mon-Sat	
		Reported: 1–3 days	
Prolactin, Dilution Study	PROLM	Special Information: removed Clinical Information: This test is useful for quantifying prolactin in serum specimens where the high-dose hook effect is suspected (e.g., presence of pituitary tumor with symptoms of prolactinoma and lower than expected serum prolactin concentration).	11/21/24
		Specimen Requirement: 1.5 mL serum from serum separator (Gold) tube; Refrigerated; Separate serum from cells and transfer into standard aliquot tube. *OR* 1.5 mL plasma from lithium heparin plasma separator (Light Green) tube; Refrigerated; Separate plasma from cells and transfer into standard aliquot tube. *OR* 1.5 mL serum from no additive (Red) tube; Refrigerated; Separate serum from cells and transfer into standard aliquot tube.	
		Stability: Ambient: After separation from cells: 7 days Refrigerated: After separation from cells: 14 days Frozen: After separation from cells: 14 days (3 freeze/thaw cycles)	
		Methodology: Electro Chemiluminescence Immunoassay (ECLIA)	
		Reference Range: Male: 4.0–15.2 ng/mL Female: 4.8–23.3 ng/mL	
		Days Performed: Varies	
		Reported: 4–5 days	
		-	

Test Name	Order Code	Change	Effective Date
Rufinamide	RUFIN	For interface clients only-Test build may need to be modified Special Information: Collect the specimen before the next dose (trough). Unacceptable conditions: Whole blood, gel separator tubes. Clinical Information: Monitoring concentrations in serum or plasma to assess drug therapy and patient compliance. Specimen Requirement: 1 mL serum from no additive (Red) tube; Refrigerated; Do not collect in a gel separator tube. Centrifuge and transfer the plasma/serum to a plastic CCL tube within 2 hours of collection and refrigerate. Transport and store at refrigerated temperature. *OR* 1 mL plasma from green lithium heparin no-gel tube; Refrigerated; Do not collect in a gel separator tube. Centrifuge and transfer the plasma/serum to a plastic CCL tube within 2 hours of collection and refrigerate. Transport and store at refrigerated temperature. Stability: Ambient: After separation from cells: 24 hours Refrigerated: After separation from cells: 14 days Frozen: After separation from cells: 30 days Methodology: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Reference Range: 3.0–30.0 ug/mL Days Performed: Mon–Sat Reported: 1–3 days	11/19/24
Testosterone, bioavailable and total by immunoassay (adult males, or individuals on testosterone therapy)	BTESTO	Name: Previously Bioavailable Testosterone,SHBG, Adult Male	11/19/24
Testosterone, bioavailable and total by MS (adult females, children, or individuals on testosterone- suppressing therapy)	BTSTFC	Name: Previously Bioavailable Testosterone/SHBG, Female & Child	11/19/24
Testosterone, free and total, by equilibrium ultrafiltration mass spectrometry	TFTEST	<ul> <li>For interface clients only–Test build may need to be modified</li> <li>Name: Previously Testosterone, Total and Free, Serum</li> <li>Special Information: NOTE: Patient's age and sex are required. Hemolyzed, icteric or grossly lipemic specimens will be rejected. Specimens from patients with recently administered isotopes will be rejected. This test is New York DOH approved.</li> <li>Clinical Information: This test is useful to evaluate hirsutism and masculinization in women, or to evaluate testicular function in clinical states in which the testosterone-binding proteins may be altered (obesity, cirrhosis, thyroid disorders). The concentration of free testosterone is very low, typically &lt;2% of the total testosterone concentration. In most men and women, &gt;50% of total circulating testosterone is bound to sex hormone-binding globulin (SHBG) and most of the rest is bound to albumin. Routinely available assay methods used to measure total testosterone are not sensitive enough to quantitate accurately the free testosterone fraction directly. Free testosterone is estimated in this profile by an indirect method, equilibrium ultrafiltration.</li> <li>Specimen Requirement: 2.2 mL serum from no additive (Red) tube; Minimum: 1.8 mL Note: Minimum volume does not allow for repeat testing; Ambient; Separate serum from cells within 1 hour and transfer to standard aliquot tube.</li> <li>Stability:</li> <li>Ambient: 7 days</li> <li>Refrigerated: 7 days</li> <li>Frozen: 5.58 years (9 freeze/thaw cycles)</li> <li>Methodology:</li> <li>Equilibrium Ultrafiltration</li> <li>High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS) (continued on page 7)</li> </ul>	effective immediately

Test Name	Order Code	Change	Effective Date
Testosterone, free and total, by equilibrium ultrafiltration mass spectrometry (continued from page 6)		Reference Range:         Testosterone, Free: Refer to report         Testosterone, Total: Refer to report         % Free Testosterone: Refer to report         Days Performed: Varies         Reported: 5–7 days	
Testosterone, total by immunoassay (adult males, or individuals on testosterone therapy)	TESTO	Name: Previously Testosterone	11/19/24
Varicella-Zoster IgG Ab	VZVG2	Clinical Limitation: Results from immunosuppressed patients should be interpreted with caution. Clinical Information: A negative result does not rule out acute infection. If exposure to Varicella-Zoster virus is suspected, despite a negative finding, a second sample should be collected and tested no less than one-two weeks later. A positive result generally indicates exposure to the pathogen or administration of specific immunoglobulins, but is no indication of active infection or stage of disease. The results are not by themselves diagnostic and should be considered in association with other clinical data and patient symptoms. Screening of the general population leads to no appreciable diagnostic advantage. The performance characteristics with individuals vaccinated with VZV (ROD strain) have not been established. Stability: Medient: 3 days Refrigerated: 7 days Frozen: 30 days	10/10/24
Vasoactive Intestinal Polypeptide (VIP), Plasma	VIP	<ul> <li>Special Information: Critical Frozen. Collect in prechilled tube. Separate specimens must be submitted when multiple tests are ordered. Grossly hemolyzed, lipemic, icteric, or clotted specimens will be rejected.</li> <li>Specimen Requirement: 2 mL plasma from EDTA (Lavender) tube; Place specimen on ice after draw. CRITICAL FROZEN. Collect in prechilled tube. Separate plasma from cells immediately and transfer to standard aliquot tube and freeze. Separate specimens must be submitted when multiple tests are ordered.</li> <li>Stability: <ul> <li>Ambient: After separation from cells: 4 hours</li> <li>Refrigerated: After separation from cells: 3 months</li> </ul> </li> <li>Reference Range: 0–89.1 pg/mL</li> <li>Days Performed: Mon, Thu</li> <li>Reported: 4–8 days</li> </ul>	10/8/24

#### New Tests

Test Name	Order Code	Change	Effective Date
Brivaracetam	BRIV	<ul> <li>Special Information: Collect the specimen before the next dose (trough).</li> <li>Unacceptable conditions: Whole blood, gel separator tubes.</li> <li>Clinical Information: Monitoring concentrations in serum or plasma to assess drug therapy and patient compliance.</li> <li>Specimen Requirement: 1 mL serum from no additive (Red) tube; Minimum: 0.5 mL; Refrigerated; Timing of specimen collection: Pre-dose (trough). Do not collect in a gel separator tube. Centrifuge and transfer the plasma/serum to a plastic CCL tube within 2 hours of collection and refrigerate. Transport and store at refrigerated temperature. *OR* 1 mL plasma from green lithium heparin no-gel tube; Minimum: 0.5 mL; Refrigerated; Timing of specimen collection: Pre-dose (trough). Do not collect in a gel separator tube. Centrifuge and transfer the plasma/serum to a plastic CCL tube within 2 hours of collection and refrigerate. Transport and store at refrigerated temperature. *OR* 1 mL plasma from green lithium heparin no-gel tube; Minimum: 0.5 mL; Refrigerated; Timing of specimen collection: Pre-dose (trough). Do not collect in a gel separator tube. Centrifuge and transfer the plasma/serum to a plastic CCL tube within 2 hours of collection and refrigerate. Transport and store at refrigerated temperature.</li> <li>Stability:</li> <li>Ambient: After separation from cells: 24 hours Refrigerated: After separation from cells: 14 days Frozen: After separation from cells: 30 days</li> <li>Methodology: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)</li> <li>Reference Range: 0.2–2.0 ug/mL</li> <li>Days Performed: Mon–Sat</li> <li>Reported: 1–3 days</li> </ul>	11/19/24
Chitotriosidase Assay	СНІТО	Note: New test was announced in the September update. Financial information was not available at that time. CPT: 84999	10/29/24
Perampanel	PRMP	<ul> <li>Special Information: Collect the specimen before the next dose (trough).</li> <li>Unacceptable conditions: Whole blood, gel separator tubes.</li> <li>Clinical Information: Monitoring concentrations in serum or plasma to assess drug therapy and patient compliance.</li> <li>Specimen Requirement: 1 mL serum from no additive (Red) tube; Minimum: 0.5 mL; Refrigerated; Timing of specimen collection: Pre-dose (trough). Do not collect in a gel separator tube. Centrifuge and transfer the plasma/serum to a plastic CCL tube within 2 hours of collection and refrigerate. Transport and store at refrigerated temperature. *OR* 1 mL plasma from green lithium heparin no-gel tube; Minimum: 0.5 mL; Refrigerated; Timing of specimen collection: Pre-dose (trough). Do not collect in a gel separator tube. Centrifuge and transfer the plasma/serum to a plastic CCL tube within 2 hours of collection and refrigerate. Transport and store at refrigerated temperature. *OR* 1 mL plasma from green lithium heparin no-gel tube; Minimum: 0.5 mL; Refrigerated; Timing of specimen collection: Pre-dose (trough). Do not collect in a gel separator tube. Centrifuge and transfer the plasma/serum to a plastic CCL tube within 2 hours of collection and refrigerate. Transport and store at refrigerated temperature.</li> <li>Stability:</li> <li>Ambient: After separation from cells: 24 hours Refrigerated: After separation from cells: 14 days Frozen: After separation from cells: 30 days</li> <li>Methodology: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)</li> <li>Reference Range: 0.18–0.98 ug/mL</li> <li>Days Performed: Mon–Sat</li> <li>Reported: 1–3 days</li> </ul>	11/19/24

#### **Discontinued Tests**

Test Name	Order Code	Test Information	Effective Date
Telomere Biology Disorders Panel	TELPAN	Test will no longer be orderable.	11/19/24